CareRx Reports 2025 Year-End and Fourth Quarter Results
CareRx Corporation (TSX: CRRX) has reported its financial results for the fourth quarter and full year ended December 31, 2025, showcasing a modest but positive growth trajectory. The company, which specializes in pharmacy services for seniors and congregate care communities, recorded a revenue increase to CAD 370.2 million for the year, up from CAD 366.7 million in 2024, and CAD 96.1 million for the fourth quarter, compared to CAD 92.2 million in the same period last year. Adjusted EBITDA also saw a rise, reaching CAD 32.9 million for the year and CAD 8.8 million for the fourth quarter, reflecting a year-over-year increase from CAD 30.3 million and CAD 7.6 million, respectively. The adjusted EBITDA margin improved to 8.9% for the year and 9.2% for the fourth quarter, up from 8.3% and 8.2% in 2024.
The increase in average beds serviced during the fourth quarter to 92,250 from 87,658 a year earlier indicates a growing operational footprint, which is crucial for CareRx's strategy of scaling its services in a sector characterized by an aging population and increasing demand for senior care. The company has also reported a significant reduction in net debt to CAD 27.1 million, down from CAD 28.8 million in the previous quarter, suggesting a strengthening balance sheet that could support further growth initiatives. Notably, CareRx commenced dividend payments in the third quarter of 2025, with a declared dividend of CAD 0.02 per share to be paid on April 9, 2026, which reflects a commitment to returning value to shareholders.
From a financial perspective, CareRx's cash from operations for the fourth quarter was CAD 9.6 million, slightly down from CAD 10.1 million in the prior quarter but an improvement from CAD 8.4 million in Q4 2024. The company's total assets stood at CAD 242.9 million, with total liabilities at CAD 133.4 million, indicating a healthy asset-to-liability ratio that supports operational stability. The company's ability to generate positive net income for the first full year, amounting to CAD 26.1 million, further underscores its operational efficiency and effective cost management strategies.
In terms of valuation, CareRx's current market capitalization is approximately CAD 215 million. When compared to direct peers such as Well Health Technologies Corp (TSX: WELL) and Lifemark Health Group (TSX: LMG), CareRx appears reasonably positioned. Well Health, which operates in a similar space, has a market cap of CAD 1.2 billion and reported an EV/EBITDA multiple of around 15x, while Lifemark, with a market cap of CAD 300 million, has an EV/EBITDA multiple of approximately 12x. CareRx's adjusted EBITDA margin of 8.9% suggests a competitive edge in operational efficiency, although its valuation metrics indicate it trades at a discount relative to its larger peer, reflecting potential market apprehension regarding its growth trajectory compared to larger competitors.
The execution track record of CareRx has been relatively stable, with management successfully meeting its operational targets and demonstrating a commitment to expanding its service offerings. However, the company faces specific risks, particularly in the form of regulatory changes in the healthcare sector, which could impact operational costs and service delivery. Additionally, the ongoing integration of newly acquired beds poses operational challenges that could affect service quality if not managed effectively.
Looking ahead, the next measurable catalyst for CareRx will be the anticipated growth in average beds serviced, which is expected to continue as home operator partners expand their facilities. The company has indicated a focus on capturing further market share, particularly as the demand for senior care services rises. The timing of these developments will be critical, with the next quarterly results expected in May 2026, which will provide further insights into the company's operational progress and financial health.
In conclusion, the announcement of CareRx's 2025 year-end and fourth-quarter results reflects a significant improvement in operational performance and financial stability. The growth in revenue and adjusted EBITDA, alongside a reduction in net debt, positions the company favorably within its sector. However, while the results are positive, they do not fundamentally alter the company's valuation or risk profile. Therefore, this announcement can be classified as moderate in terms of materiality, indicating incremental progress rather than a transformational shift in the company's outlook.